Aprocitentan, sold under the brand name Tryvio, is a medication used to treat
hypertension (high blood pressure).[1] It is developed by
Idorsia.[2] It is taken
by mouth.[1]
Aprocitentan is
indicated for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adults who are not adequately controlled on other medications.[1]
Data from animal reproductive toxicity studies with other endothelin-receptor agonists indicate that use is contraindicated in pregnant women.[1]
Mechanism of action
Aprocitentan is an endothelin receptor antagonist that inhibits the protein endothelin-1 from binding to endothelin A and endothelin B receptors.[1][4] Endothelin-1 mediates various adverse effects via its receptors, such as
inflammation,
cell proliferation,
fibrosis, and
vasoconstriction.[1]
Society and culture
Economics
Aprocitentan is developed by
Idorsia, which sold it to
Janssen and purchased the rights back in 2023, for US$343 million.[6]
Legal status
Aprocitentan was approved for medical use in the United States in March 2024.[1]
In April 2024, the
Committee for Medicinal Products for Human Use (CHMP) of the
European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Jeraygo, intended for the treatment of resistant hypertension in adults.[7] The applicant for this medicinal product is Idorsia Pharmaceuticals Deutschland GmbH.[7]
^
ab"Jeraygo EPAR". European Medicines Agency. 25 April 2024.
Archived from the original on 30 April 2024. Retrieved 27 April 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
Further reading
Mahfooz K, Najeed S, Tun HN, Khamosh M, Grewal D, Hussain A, et al. (July 2023). "New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension: A Systematic Review and Meta-Analysis". Current Problems in Cardiology. 48 (7): 101686.
doi:
10.1016/j.cpcardiol.2023.101686.
PMID36893968.